Prices delayed by at least 15 minutes | Print


KalVista Pharmaceuticals (KALV)

Common Shares
Sell: $11.6|Buy: $16|Change: 0.79 (7.14%)

Open 

$11.08


Previous close 

$11.07


Trade high 

$12.4555


Volume 

2,152,861


Year high 

$16.88


Year low 

$6.83


Dividend yield 

-


Market capitalisation 

$500.35 mn


P/E ratio 

-


ISIN 

US4834971032


This share can be held in a Dealing accountISALifetime ISAJISASIPP

Share price

Performance 31/03/2024

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann


Total return (%)
KalVista Pharmaceuticals+ 7.14
More...

Company profile

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.

Sector 

Healthcare


AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.